stockrow
Saturday 7 November 2026
Export EOCN’s income statement to Excel — free account
Eocene Ltd.
EOCN Healthcare Biotechnology
- EPS
- +43.3%
- Free cash flow
- −67.7%
Quarter to June 2026, against a year earlier
2.74
0.29
+11.84%
Follow EOCN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 0 | 1 | 2 | — | — | — | — | — | — | — | 2 | +108.9% | 0 | 0 | 2 | +200.1% | |
| Gross margin, % | 100.00 | 100.00 | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | (100.0) pt | ||||||
| EBT | (17) | (12) | (10) | (20) | (29) | (32) | (18) | (7) | (8) | (10) | (11) | (5.3%) | ||||||
| EBT margin, % | (3,607.49) | (1,133.55) | (479.93) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +3,607.5 pt | ||||||
| Net income | (17) | (12) | (10) | (20) | (29) | (32) | (18) | (7) | (8) | (10) | (11) | (5.4%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 59.11 | 124.71 | 161.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (2,145.39) | (1,411.06) | (777.52) | (1,396.66) | (1,943.81) | (1,900.61) | (1,022.30) | (240.10) | (64.64) | (19.12) | (14.20) | (40.8%) | ||||||
| Cash flow | (1,535.32) | (1,387.01) | (716.11) | (1,016.12) | (1,776.15) | (1,923.51) | (1,057.20) | (213.09) | (50.52) | (11.72) | (8.97) | (41.8%) | ||||||
| Capex | (0.51) | (1.38) | (7.14) | (0.82) | (2.97) | (0.64) | (0.23) | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (1,535.82) | (1,388.39) | (723.25) | (1,016.94) | (1,779.12) | (1,924.15) | (1,057.43) | (213.09) | (50.52) | (11.72) | (8.97) | (41.8%) | ||||||
| Book value | 1,401.90 | 1,815.52 | 6,975.71 | 4,751.90 | 2,983.31 | 1,783.45 | 767.03 | 481.91 | 140.27 | 29.29 | 13.38 | (34.9%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | +59.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | 0.00 | 108.42 | 60.81 | — | — | — | — | — | — | — | 1.28 | 56.4 | ||||||
| P/B | 3.73 | 7.45 | 1.41 | — | — | — | — | — | — | — | 0.20 | 4.2 | ||||||
| EV/Sales | 0.00 | 90.91 | 19.53 | — | — | — | — | — | — | — | (3.06) | 36.8 | ||||||
| EV/FCF | (2.13) | (8.17) | (4.37) | — | — | — | — | — | — | — | 0.73 | (4.9) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (12) | (12) | (9) | (15) | (26) | (33) | (19) | (6) | (6) | (6) | (9) | (7.0%) | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0 | 0.0% | ||||||
| Free cash flow | (12) | (12) | (9) | (15) | (26) | (33) | (19) | (6) | (6) | (6) | (9) | (7.0%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 11 | 15 | 88 | 69 | 44 | 30 | 12 | 10 | 14 | 16 | 9 | +3.9% | |||||
| Net debt | (15) | (19) | (84) | (47) | (47) | (35) | (14) | (11) | (12) | (11) | (9) | (3.6%) | ||||||
| Shareholders’ equity | 11 | 16 | 88 | 70 | 44 | 30 | 13 | 14 | 16 | 16 | 13 | +4.0% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (83.28) | (68.15) | (17.88) | (24.40) | (44.43) | (72.97) | (67.21) | (41.65) | (42.80) | (55.53) | (55.03) | +27.7 pt | |||||
| ROIC | 0.00 | 0.00 | (177.49) | (62.05) | 0.00 | 0.00 | 0.00 | (138.82) | (89.77) | (114.43) | (163.19) | (114.4) pt | ||||||
| ROE | (103.94) | (91.54) | (19.01) | (25.94) | (50.47) | (86.98) | (81.36) | (50.63) | (49.77) | (64.21) | (68.21) | +39.7 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 16 | 17 | 21 | 21 | 24 | 24 | 10 | 8 | 6 | 9 | — | (6.2%) | |||||
| Revenue/emp, $m | 0.03 | 0.06 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2018 · latest quarter Dec 2018 · fundamentals updated 25 Oct 2026
Eocene Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| JUNS Jupiter Neurosciences, Inc. | $2.8M | — (loss-making) | — | — | n/m | −177.06% (below 0%: shrinking) | 87.19% | (11,334.30%) | Compare |
| AFMDQ Affimed N.V. | $2.8M | — (loss-making) | — (loss-making) | −92.02% (below 0%: shrinking) | n/m | +46.95% (above 0%: growing) | 100.00% | (9,216.90%) | Compare |
| DCOY Decoy Therapeutics Inc | $2.7M | — (loss-making) | — (loss-making) | −84.61% (below 0%: shrinking) | n/m | −212.47% (below 0%: shrinking) | 100.00% | (1,055.98%) | Compare |
| NRSN NeuroSense Therapeutics Ltd. | $2.6M | — (loss-making) | — | — | n/m | −23,458.82% (below 0%: shrinking) | — | 0.00% | Compare |
| EOCN Eocene Ltd. | $2.6M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −67.74% (below 0%: shrinking) | 0.00% | 0.00% | |
| BIORQ Biora Therapeutics, Inc. | $2.5M | — (loss-making) | — (loss-making) | +1,500.00% (above 0%: growing) | n/m | +20.72% (above 0%: growing) | 100.00% | (50,709.38%) | Compare |
| CLDI Calidi Biotherapeutics, Inc. | $2.5M | — (loss-making) | — | — | n/m | +11.16% (above 0%: growing) | — | 0.00% | Compare |
| WINT Windtree Therapeutics, Inc. | $2.4M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +1.12% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VIVS VivoSim Labs, Inc. | $2.3M | — (loss-making) | — (loss-making) | −51.35% (below 0%: shrinking) | n/m | +17.87% (above 0%: growing) | 100.00% | (15,327.78%) | Compare |
| Median of peers | $2.6M | — | — | −84.61% | — | +6.14% | 100.00% | (5,136.44%) |